A Phase II, multicentre, randomised, double blind, parallel-group, placebo controlled study to investigate the efficacy and safety of RO4602522 added to background Alzheimer’s Disease therapy in patients with moderate severity Alzheimer’s Disease.
DEMENTIA TRIALS AUSTRALIA